We provide you with 20 years of free, institutional-grade data for NRXS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of NRXS. Explore the full financial landscape of NRXS stock.
| Reported Date | CIK | Ticker | Type |
|---|
Neuraxis Inc.(NYSE MKT:NRXS) 
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare ...
Website: https://neuraxis.com/
Founded: 2011
IPO Price: $6 (Aug 09, 2023)
Full Time Employees: 17
Sector: Biotechnology
Industry: Healthcare
Share this website to your friends
The information provided in this report about NRXS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.